Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients With Relapse / Refractory Metastatic or Advanced Solid Tumors

NCT05052255 is registered in ClinicalTrials.gov with Ryvu Therapeutics SA as lead sponsor.

NCT NCT05052255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05052255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients With Relapse / Refractory Metastatic or Advanced Solid Tumors
Lead sponsor
Ryvu Therapeutics SA
Phase
Phase 1/2
Overall status
Terminated
Start date
August 13, 2021
Completion date
October 2, 2025
Enrollment
66 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor